Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

Valued at $13 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...